Halozyme Therapeutics | HALO - Debt

Stock Price
80.82
Daily Change
2.40 3.06%
Monthly
7.60%
Yearly
41.54%
Q1 Forecast
69.50

Halozyme Therapeutics reported $1.51B in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
Agios Pharmaceuticals USD 48.76M 47.62M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amarin USD 0 0 Mar/2025
Amgen USD 54.59B 1.62B Sep/2025
Baxter International USD 9.73B 584M Jun/2025
Cytokinetics USD 858.06M 199.93M Jun/2025
DBV Technologies USD 8.59M 295K Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
MannKind USD 46.82M 243.3M Jun/2025
Pfizer USD 60.85B 78M Sep/2025
United Therapeutics USD 200M 100M Mar/2025